Sentences with phrase «myeloma at»

Conventional treatment helped keep the myeloma at bay, yet sadly he passed away at the age of 62 from amyloidosis, a complication of the multiple myeloma.

Eppie died of multiple myeloma at age 83, while Pauline lived to be 94 before succumbing to Alzheimer's disease this year.

«We are defeating leukemia, lymphoma, and myeloma at increasing rates.

In the U.S., it is estimated that 1 in 150 men and women will develop myeloma at some point in their lifetimes.

«The lifetime risk of these cancers is fairly low - about one in 20 men and women will be diagnosed with lymphoma, leukemia, or myeloma at some point during their lifetime — so people born to older fathers should not be alarmed,» said Dr. Teras.

The authors speculate the reasons for the prolonged survival in their study is that patients with MGUS are evaluated more often for signs of progression to MM and may be diagnosed and started on therapy for myeloma at an earlier stage.

«Today, we have half a dozen drugs for multiple myeloma that can put patients into remission,» said Tomasson, who treats patients with multiple myeloma at Siteman Cancer Center at Barnes - Jewish Hospital and Washington University School of Medicine.

Not exact matches

And that, of course, was a very different reason from the one that had brought him and his fellow lunch mates to gather that afternoon — at a day of scientific panels and presentations sponsored by the Multiple Myeloma Research Foundation.

«This approval will open the floodgates for these kinds of therapy to be used in many different leukemias, lymphomas, solid tumors, myelomas,» Dr. Prakash Satwani, a pediatric hematologist - oncologist at Columbia University Medical Center, told Business Insider.

Juno also has a few other compounds in early stages of development aimed at treating NHL, pediatric ALL, multiple myeloma, ovarian & breast cancer, AML, lung cancer, and more.

The FDA approved Kyprolis for patients who have already been treated with at least two other multiple myeloma drugs, and Onyx is conducting other trials to win broader marketing approval.

After his illness was diagnosed, Mr. Cassidy organized two fundraisers at Buffalo Grove High School: a «liftathon,» in which teams of students and staff lifted weights for pledges for the International Myeloma Foundation, and a «walkathon» for cancer research.

«Several major advances in recent years have been good news for multiple myeloma patients, but those new drugs only target terminally differentiated cancer cells and thus can only reduce the bulk of the tumor,» said Jamieson, who is also deputy director of the Sanford Stem Cell Clinical Center, director of the CIRM Alpha Stem Cell Clinic at UC San Diego and director of stem cell research at Moores Cancer Center at UC San Diego Health.

To unravel exactly how ADAR1 is connected to disease severity at a molecular level, the researchers transferred multiple myeloma patient tissue to mice, creating what's known as a xenograft or «humanized» model.

«Despite new therapies, it's virtually inevitable that a patient with multiple myeloma will experience relapse of the disease at some point,» said senior author Catriona Jamieson, MD, PhD, professor of medicine, Koman Family Presidential Endowed Chair in Cancer Research and chief of the Division of Regenerative Medicine at UC San Diego School of Medicine.

Senior author Madhav Dhodapkar, M.D., the Arthur H. and Isabel Bunker Professor of Medicine and Immunobiology, and chief of Hematology, said the study, using tissue and blood samples from humans and mice, shows that chronic stimulation of the immune system by lipids made in the context of inflammation underlies the origins of at least a third of all myeloma cases.

In a trio of studies to be presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, investigators at Dana - Farber Cancer Institute will present the results of clinical trials showing that new drug combinations can significantly extend the time in which multiple myeloma is kept in check in patients with relapsed or treatment - resistant forms of the disease.

Myeloma is often called multiple myeloma because it occurs at many sites within the bone Myeloma is often called multiple myeloma because it occurs at many sites within the bone myeloma because it occurs at many sites within the bone marrow.

«In summary, these encouraging data build upon the real success of our translational efforts in myeloma over the last decade, and provide exciting new options with the real promise of improving patient outcome,» said Richardson, who is also the R.J. Corman professor at Harvard Medical School.

The U.S. Food and Drug Administration approved the drug on Nov. 20 for patients with myeloma who have received at least one previous therapy.

Researchers at Washington University School of Medicine in St. Louis have developed a nanotherapy that is effective in treating mice with multiple myeloma, a cancer of bone marrow immune cells.

«But our findings show that obesity can now be defined as a risk factor for developing multiple myeloma through this condition,» said the study's first author, Su - Hsin Chang, PhD, an assistant professor of surgery in the Division of Public Health Sciences at Washington University.

The group looked at an oncogene, AF1q discovered in Tse's lab, which is expressed in hematological cancer cells and is known to be related to multiple myeloma.

«There are clearly molecular differences between African - American and Caucasian multiple myeloma cases, and it will be critical to pursue these observations to better improve clinical management of the disease for all patients,» said John D. Carpten, senior author of the study and chair of the Department of Translational Genomics at the Keck School of Medicine.

«We are excited by the work of Dr. Pourdehnad and colleagues and believe these results are an important advance in understanding the role of myc pathway dysregulation in multiple myeloma, and ultimately allow for the development of therapeutic strategies to address it,» said Jeffrey Wolf, MD, a UCSF blood disorder specialist and director of the Stephen and Nancy Grand Multiple Myeloma Translational Initiative at UCSF, a sponsor of the remyeloma, and ultimately allow for the development of therapeutic strategies to address it,» said Jeffrey Wolf, MD, a UCSF blood disorder specialist and director of the Stephen and Nancy Grand Multiple Myeloma Translational Initiative at UCSF, a sponsor of the reMyeloma Translational Initiative at UCSF, a sponsor of the research.

That trend is problematic considering that African - Americans — the most at - risk population for multiple myeloma — have different genetics that can affect how this type of cancer progresses and what kind of targeted therapies are most effective, said Zarko Manojlovic, lead author of the study.

Using an approach developed at Maisonneuve - Rosemont, consisting of an autograft to reduce tumour mass followed by a family allograft three to four months later to clean the bone marrow of myeloma cells with immune cells from a family donor (immunotherapy), the study resulted in a total cure rate of 41 %, a record level using this strategy.

«The treatment of multiple myeloma has improved significantly in recent years with the introduction of therapies such as proteasome inhibitors [which interfere with tumor cells» protein - disposal system] and potent immuno - modulatory agents,» said the paper's senior author and lead investigator, Paul Richardson, MD, clinical program leader and director of clinical research at Dana - Farber's Jerome Lipper Multiple Myeloma Center, and the R.J. Corman professor at Harvard Medical myeloma has improved significantly in recent years with the introduction of therapies such as proteasome inhibitors [which interfere with tumor cells» protein - disposal system] and potent immuno - modulatory agents,» said the paper's senior author and lead investigator, Paul Richardson, MD, clinical program leader and director of clinical research at Dana - Farber's Jerome Lipper Multiple Myeloma Center, and the R.J. Corman professor at Harvard Medical Myeloma Center, and the R.J. Corman professor at Harvard Medical School.

The 2 - year trial will treat 18 people with myeloma, sarcoma, or melanoma who have stopped responding to existing treatments at three sites that are members of the Parker Institute — UPenn; the University of California, San Francisco; and the University of Texas MD Anderson Cancer Center in Houston.

In its first clinical trial, a breakthrough antibody therapy produced at least partial remissions in a third of patients with multiple myeloma who had exhausted multiple prior treatments, investigators at Dana - Farber Cancer Institute and other organizations report today online in the New England Journal of Medicine.

In 2004 he began postdoctoral work at the University of North Carolina Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, investigating the role of EBV lytic infection and the role of HDM - 2 inhibitors in myeloma and lymphoma treatment.

Researchers at MIT have now shown that they can use a new type of measurement to predict how drugs will affect cancer cells taken from multiple - myeloma patients.

«We've known about these cells blocking immune response for a decade, but haven't been able to shut them down for lack of an identified target,» said the paper's senior author, Larry Kwak, M.D., Ph.D., chair of Lymphoma / Myeloma and director of the Center for Cancer Immunology Research at The University of Texas MD Anderson Cancer Center.

«Our group, which includes more than 180 myeloma researchers worldwide, has updated the definition of multiple myeloma for diagnostic purposes to include validated biomarkers in addition to the current clinical symptoms used for diagnosis which include, elevated blood calcium levels, kidney failure, anemia and bone lesions,» said lead author S. Vincent Rajkumar, M.D. a hematologist at Mayo Clinic.

A multiple myeloma patient whose cancer had stopped responding after nine different treatment regimens experienced a complete remission after receiving an investigational personalized cellular therapy known as CTL019 developed by a team at the University of Pennsylvania.

Although it is among the most highly metastatic of all cancers, multiple myeloma is driven to spread by only a subset of the myeloma cells within a patient's body, researchers at Dana - Farber Cancer Institute have found in a study presented at the annual meeting of the American Society of Hematology (ASH).

A new study by researchers at The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James) provides evidence that genetically modifying immune cells might effectively treat multiple myeloma, a disease that remains incurable and will account for an estimated 24,000 new cases and 11,100 deaths in 2014

This research provides the basis for developing new and more targeted treatments and minimally invasive ways of identifying those MGUS patients at risk of progressing to myeloma.

Dr Daniel Tennant, who led the research at the University of Birmingham, said, «Our findings show that very few changes are required for a MGUS patient to progress to myeloma as we now know virtually all patients with myeloma evolve from MGUS.

Dr Matt Kaiser, Head of Research at Bloodwise, said, «Myeloma is a devastating cancer that can cause debilitating and painful bone damage and, although we have become better at treating it and extending the lives of myeloma patients, it is ultimately almost alwaysMyeloma is a devastating cancer that can cause debilitating and painful bone damage and, although we have become better at treating it and extending the lives of myeloma patients, it is ultimately almost alwaysmyeloma patients, it is ultimately almost always fatal.

Multiple myeloma patients got some good news on November 16 — the immunotherapy daratumumab (Darzalex ®) was given approval by the FDA for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy.

Amrita Krishnan, M.D., F.A.C.P., is Director of the Multiple Myeloma Program at City of Hope.

Martin Carroll, MD and Edward Stadtmauer, MD are leading efforts at this TCE to redefine the diagnostic and therapeutic approaches to blood cancers — including leukemia, lymphoma and myeloma — and provide more effective targeted therapies.

«The surprising result was embodied by checkpoint expression in extramedullary myeloma showing that these lesions are able to reproduce their environment out of the bone,» said study co-author Alba Grifoni, PhD, from the Division of Vaccine Discovery at La Jolla Institute for Allergy and Immunology in La Jolla, California.

Preliminary findings presented at ASH suggest a «favorable emerging clinical profile» for once weekly administration of MLN9708 in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.

At UT Southwestern Medical Center, our experts specialize in treatment for every stage of myeloma.

While myeloma is not curable, it is treatable, especially at a top cancer center like UT Southwestern that has the newest therapies.

No Place Like Home Rebecca Zoltoski was the first patient at the University of Chicago Medicine to undergo a blood and bone marrow stem cell transplant as an outpatient for her multiple myeloma.

At the University of Chicago Medicine campus, the hematologists / oncologists on our multiple myeloma team are nationally known experts in the treatment of this disease.

«We explored the relationship between response to initial treatment and survival in patients with newly diagnosed multiple myeloma, based on data from 63 randomized clinical trials,» wrote researcher Maria Mainou, of the clinical research and evidence - based medicine unit at Aristotle University of Thessaloniki, Greece, and colleagues.